Back to Search Start Over

Near-infrared fluorescence lymphatic imaging in vascular endothelial growth factor-C overexpressing murine melanoma.

Authors :
Kwon S
Velasquez FC
Sevick-Muraca EM
Source :
Biomedical optics express [Biomed Opt Express] 2018 Sep 04; Vol. 9 (10), pp. 4631-4637. Date of Electronic Publication: 2018 Sep 04 (Print Publication: 2018).
Publication Year :
2018

Abstract

In this study we employ a near-infrared fluorescence lymphatic imaging (NIRFLI) technique to longitudinally image spatial and temporal changes in the lymphatics in mice bearing vascular endothelial growth factor (VEGF)-C overexpressing B16F10 (VEGF-C-B16F10) or mock-transduced B16F10 (mock-B16F10) melanoma tumors. Our NIRFLI data show that ICG-laden lymph accumulates into a VEGF-C-B16F10 tumor compared to mock-B16F10 at 3 days post implantation, presumably due to increased lymphatic vessel permeability. Quantification shows a significantly greater percentage of ICG-perfused area in VEGF-C-B16F10 (7.6 ± 2) as compared to MOCK-B16F10 (1 ± 0.5; p = 0.02), which is also confirmed by quantification of the lymphatic leakage of evans blue dye (optical density at 610nm; VEGF-C-B16F10, 10.5 ± 2; mock-B16F10, 5.1 ± 0.5; p = 0.009); thereafter, lymphatic leakage is visualized only in the peritumoral region. Our imaging data also show that anti-VEGF-C treatment in VEGF-C-B16F10 restores normal lymphatic vessel integrity and reduces dye extravasation. Because NIRFLI technology can be used to non-invasively detect lymphatic changes associated with cancer, it may provide a new diagnostic to assess the lack of lymphatic vessel integrity that promotes lymphovascular invasion and to assess therapies that could arrest invasion through normalization of the lymphatic vasculature.<br />Competing Interests: The authors declare that there are no conflicts of interest related to this article.

Details

Language :
English
ISSN :
2156-7085
Volume :
9
Issue :
10
Database :
MEDLINE
Journal :
Biomedical optics express
Publication Type :
Academic Journal
Accession number :
30319891
Full Text :
https://doi.org/10.1364/BOE.9.004631